<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00225082</url>
  </required_header>
  <id_info>
    <org_study_id>SNAP</org_study_id>
    <nct_id>NCT00225082</nct_id>
  </id_info>
  <brief_title>SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function</brief_title>
  <official_title>SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV infected subjects receiving antiretroviral treatment for greater than 6 years with be
      evaluated for clinical lipoatrophy and mitochondrial function after switching nucleoside
      analogues from stavudine (d4T) to tenofovir treatment and after 4.

      Hypothesis: Tenofovir therapy will increase peripheral fat content as assessed by DEXA and
      mitochondrial function at 48 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV infected subjects receiving antiretroviral treatment (lopinavir/ritonavir, stavudine, and
      lamivudine) for greater than 6 years through the Abbott M97-720 protocol with be evaluated
      for clinical lipoatrophy and mitochondrial function prior to switching nucleoside analogues
      from stavudine (d4T) to tenofovir and after 48 weeks or tenofovir treatment.

      Subjects with or without lipoatrophy are eligible for the study. Adipose tissue biopsies to
      measure mitochondrial function, metabolic laboratory tests, and DAXA scans and clinical
      evaluations of lipodystrophy will be performed at Entry and after 48 weeks of tenofovir
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">12</enrollment>
  <condition>HIV Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nucleoside analogue switch</intervention_name>
    <description>stavudine switched to tenofovir</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      adipose tissue, blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV infected subjects receiving antiretroviral treatment (lopinavir/ritonavir, stavudine,
        and lamivudine) for greater than 6 years through the Abbott M97-720 protocol with be
        evaluated for clinical lipoatrophy and mitochondrial function prior to switching nucleoside
        analogues from stavudine (d4T) to tenofovir and after 48 weeks or tenofovir treatment.
        Subjects with or without lipoatrophy are eligible for the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infection

          -  Receiving Kaletra, stavudine, and lamivudine for greater than 6 years (through Abbott
             M97-720 study)

          -  Planning to switch from stavudine to tenofovir

        Exclusion Criteria:

          -  Will continue to receive stavudine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert L Murphy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mariana Gerschenson, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Hawaii</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gerschenson M, Kim C, Berzins B, Taiwo B, Libutti DE, Choi J, Chen D, Weinstein J, Shore J, da Silva B, Belsey E, McComsey GA, Murphy RL. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother. 2009 Jun;63(6):1244-50. doi: 10.1093/jac/dkp100. Epub 2009 Mar 25.</citation>
    <PMID>19321503</PMID>
  </results_reference>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2005</study_first_submitted>
  <study_first_submitted_qc>September 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2005</study_first_posted>
  <last_update_submitted>October 4, 2010</last_update_submitted>
  <last_update_submitted_qc>October 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Robert Murphy, MD</name_title>
    <organization>Northwestern University</organization>
  </responsible_party>
  <keyword>Lipoatrophy</keyword>
  <keyword>Mitochondrial function</keyword>
  <keyword>Nucleoside analogue switch</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

